The VUB-VIB Bio Incubator Brussels ©Thierry Geenen

VUB and VIB launch new Bio Incubator Brussels on VUB campus

Catalyst for collaboration and biotechnological innovation

The Vrije Universiteit Brussel (VUB) and VIB have joined forces to launch the brand-new Bio Incubator Brussels (BIB) on the green VUB Main Campus in Etterbeek. This innovative hub brings together science, technology, and entrepreneurship to transform groundbreaking biotechnological advancements into new companies. Start-ups in the fields of biotechnology, pharmaceuticals, and health technology can now utilize this facility, which offers ready-to-use lab and office spaces. The VIB Nanobody Core Facility was the first to move in.

The bio-incubator was established on the initiative of and with financial support from the VIB-VUB Center for Structural Biology. This research center, led by Jan Steyaert and Han Remaut, has a strong track record of successful biotech spin-offs, such as Ablynx, Biotalys, and Confo Therapeutics.

“With this new bio-incubator, we aim to facilitate the creation of start-ups in their early stages and strengthen the link between our lab and our spin-offs,” says Prof. Jan Steyaert, Scientific Director of the VIB-VUB Center for Structural Biology.

Bridge between innovation and collaboration

The Bio Incubator Brussels offers a stimulating ecosystem for innovation and scientific collaboration. The spaces are equipped with state-of-the-art lab furniture and include shared lab facilities, modern office spaces, and a wide range of support services. These services include mentorship, networking opportunities, and direct access to academic talent and industrial partners closely associated with the university and institute.

Jan Danckaert, rector of the VUB, highlights the incubator’s importance: “The establishment of the Bio Incubator Brussels reinforces the VUB’s role in translating scientific research into societal and economic applications. It is a critical platform that will shape an ecosystem for companies and scientists to collaborate on solutions and applications in life sciences and health technology that will make a difference in the near future.”

VIB Nanobody Core Facility takes the lead

The first organization to set up in the bio-incubator is the VIB Nanobody Core Facility. This facility specializes in developing nanobodies, unique antibodies used in the biomedical and pharmaceutical sectors to create new treatments.

Dr. Gholamreza Hassanzadeh Ghassabeh, head of the Nanobody Core Facility, expressed his enthusiasm: “Bio Incubator Brussels provides us with the opportunity to further develop our research on nanobodies in a stimulating environment, surrounded by experts and companies who can support our innovation process. This is a fantastic chance to link scientific progress with commercial applications that can make a real impact on healthcare.”

For more information and to arrange a visit, go to https://www.vubtechtransfer.be/bio-incubator-brussels-bib.

Pictures © Thierry Geenen

 


Contact

David Moreels

​Incubator Manager VUB 

​0488 66 67 95 

david.moreels@vub.be 

Jan Steyaert

​Scientific Director VIB-VUB Center for Structural Biology

​0495 27 02 48 

jan.steyaert@vub.be

www.steyaertlab.be ​ ​ 

 

 

 

 

 

Share

Latest stories

Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be
Website preview
Brain immune cells may help build Alzheimer’s plaques
A new study led by researchers from VIB and KU Leuven shows that immune cells called microglia can actively promote the formation of plaques in Alzheimer’s disease, challenging the long-standing view that these cells serve only as defenders against plaque buildup. The findings were recently published in PNAS.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be